AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22247115
Drug: Probiotics and
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics and organic acids (1 g/L in water) for 14 days (T3)
Trial: 18801576
Drug: Combined phacotrabeculectomy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined phacotrabeculectomy with adjunctive mitomycin C
Trial: 17258092
Drug: 25-microg low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25-microg low-dose (LD) UCN 2
Trial: 17258092
Drug: 100-microg high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-microg high-dose (HD) UCN 2
Trial: 9842626
Drug: Behavioural hearing
RxNorm normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioural hearing tactics treatment
Trial: 2678684
Drug: Antiandrogens monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiandrogens monotherapy
Trial: 2678684
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with antiandrogens and castration
Trial: 1102567
Drug: Glucagon (1-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (1-mg dose)
Trial: 30982953
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (DEX) 3.28 μg kg-1
Trial: 25277638
Drug: Morphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine plus remifentanil (MR)
Trial: 23719683
Drug: Oral rhPTH(1-31)NH2
RxNorm normalized name: GHRH(1-44)NH2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rhPTH(1-31)NH2 tablets (5 mg)
Trial: 23719683
Drug: Subcutaneous teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous teriparatide (20 μg daily)
Trial: 19512867
Drug: Buspirone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (60 mg orally)
Trial: 19512867
Drug: Dexmedetomidine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (intravenous infusion to target plasma concentration of 0.6 ng/ml)
Trial: 19512867
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of buspirone and dexmedetomidine
Trial: 16679090
Drug: Atorvastatin (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (group I)
Trial: 15596193
Drug: Goserelin 10.8
RxNorm normalized name: goserelin 10.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin 10.8 mg every 84 days
Trial: 15596193
Drug: Goserelin 3.6
RxNorm normalized name: goserelin 3.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin 3.6 mg every 28 days
Trial: 90859
Drug: Preoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intravenous metronidazole
Trial: 7846337
Drug: Intravenous normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline (control)
Trial: 27649551
Drug: Concurrent 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent 50 Gy (in 4 fractions) to liver
Trial: 27649551
Drug: Sequential 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential 50 Gy (in 4 fractions) to liver
Trial: 27649551
Drug: Concurrent 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent 50 Gy (in 4 fractions) to lung
Trial: 27649551
Drug: Sequential 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential 50 Gy (in 4 fractions) to lung
Trial: 27649551
Drug: Sequential 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential 60 Gy (in 10 fractions) to lung or liver
Trial: 21232669
Drug: Vernakalant (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vernakalant (3 mg/kg infusion for 10 min, followed by a 15-min observation, and a second infusion of 2 mg/kg if still in AF)
Trial: 21232669
Drug: Amiodarone (60-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (60-min infusion of 5 mg/kg followed by a maintenance infusion of 50 mg over an additional 60 min)
Trial: 19143902
Drug: Valacyclovir 2
RxNorm normalized name: valacyclovir 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 2 g orally twice daily for 1 day and clobetasol gel 0.05% twice daily for 3 days
Trial: 15093954
Drug: Paroxetine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20-40 mg) plus Pindolol (5 mg)
Trial: 11428178
Drug: Wild yam
RxNorm normalized name: wild yam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wild yam cream
Trial: 9679620
Drug: Enalapril (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (15 mg once daily)
Trial: 9679620
Drug: Captopril (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (2-4 times daily)
Trial: 1793422
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural group therapy (CBGT) for a period of 3 months
Trial: 1793422
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural group therapy (CBGT)
Trial: 6871067
Drug: Nuelin Depot
RxNorm normalized name: Nuelin S.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuelin Depot 350 mg with antacid
Trial: 6871067
Drug: Theo-Dur 300
RxNorm normalized name: Theo-Dur 300mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theo-Dur 300 mg with antacid
Trial: 6871067
Drug: Nuelin Depot
RxNorm normalized name: Nuelin S.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuelin Depot 350 mg without antacid
Trial: 6871067
Drug: Theo-Dur 300
RxNorm normalized name: Theo-Dur 300mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theo-Dur 300 mg without antacid
Trial: 30775145
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of oral cephalexin
Trial: 22829849
Drug: Single allogenic
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single allogenic mesenchymal stem cells transplantation (MSCT) at a dose of one million MSCs per kilogram of body weight.
Trial: 18823912
Drug: Barcode medication
RxNorm normalized name: ECHINACEA PURPUREA WHOLE 3 [hp_X] in 1 mL / VIROLA SEBIFERA RESIN 4 [hp_X] in 1 mL / ATROPA BELLADONNA 6 [hp_X] in 1 mL / CALCIUM SULFATE ANHYDROUS 6 [hp_X] in 1 mL / LAMB 6 [hp_X] in 1 mL / ARSENIC TRIOXIDE 8 [hp_X] in 1 mL / SILICON DIOXIDE 9 [hp_X] in 1 mL / SULFUR IODIDE 10 [hp_X] in 1 mL / CALCIUM FLUORIDE 12 [hp_X] in 1 mL / CALCIUM SULFIDE 121 [hp_X] in 1 mL / LACHESIS MUTA VENOM 12 [hp_X] in 1 mL ORAL SPRAY [Thymus Sarcode]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barcode medication administration (BCMA) system
Trial: 15939922
Drug: FOLFIRI (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI (irinotecan 180 mg/m(2) on day 1 with LV 100 mg/m(2) and FU 400 mg/m(2) bolus, FU 600 mg/m(2) infusion)
Trial: 15939922
Drug: FOLFOX4 (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 (oxaliplatin 85 mg/m(2) on day 1 with LV5FU2 regimen)
Trial: 30348460
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg on day 0, 10 mg on day 1, 5 mg on day 2)
Trial: 23830536
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard treatment only)
Trial: 26231498
Drug: Psilocybin (moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (moderate dose)
Trial: 24494286
Drug: Electroacupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture plus warm needling therapy (EA + WN)
Trial: 24494286
Drug: Warm needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm needling therapy (WN)
Trial: 10816184
Drug: Daily interruption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interruption of sedative infusions
Trial: 17531920
Drug: Cigarette smoking
RxNorm normalized name: Cigarette smoking tobacco
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette smoking (nicotine content, 0.9 mg)
Trial: 14745677
Drug: Heparin surface-modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin surface-modified PMMA intraocular lenses (HSM-IOLs)
Trial: 28052885
Drug: Micronutrient-fortified young-child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient-fortified young-child formula (YCF) (1.2 mg Fe/100 mL; 1.7 μg vitamin D/100 mL)
Trial: 28052885
Drug: Nonfortified cow
RxNorm normalized name: Cow milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonfortified cow milk (CM) (0.02 mg Fe/100 mL; no vitamin D)
Trial: 22360365
Drug: G-Cem (GC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Cem (GC, Japan)
Trial: 20060790
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg cefuroxime tablet
Trial: 15501926
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (acute: bolus 0.06; drip 0.02 g/kg fat-free mass)
Trial: 15501926
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (chronic: 500 mg/day for 30 days)
Trial: 11772423
Drug: Postmenopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postmenopausal hormone replacement therapy
Trial: 9788685
Drug: Cetirizine 5
RxNorm normalized name: cetirizine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 5 mg with sustained-release pseudoephedrine (PSE) 120 mg
Trial: 7658780
Drug: Controlled-release melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release melatonin (2 mg per night for 3 weeks)
Trial: 2501598
Drug: Nitroglycerin (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (transdermal administration via Nitroderm TTS 10 for 48 hours)
Trial: 20819983
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication alone
Trial: 29444522
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (antipsychotic medication + psychosocial intervention)
Trial: 27502589
Drug: ACEMg (β-carotene,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEMg (β-carotene, ascorbic acid, dl-α-tocopherol acetate, magnesium) administered twice daily for approximately 3 months
Trial: 27502589
Drug: ACEMg treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEMg treatment
Trial: 23479993
Drug: OCA7 (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA7 (omeprazole 0.04 g/day, clarithromycin 1 g/day, amoxicillin 2 g/day for 7 days)
Trial: 23479993
Drug: OCA14 (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA14 (same drugs for 14 days)
Trial: 23479993
Drug: OCA7L1 (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA7L1 (same drugs for 7 days + glucosaminylmuramyldipeptide 0.001 g/day for 1 day)
Trial: 23479993
Drug: OCA7L10 (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA7L10 (same drugs for 7 days + glucosaminylmuramyldipeptide 0.01 g/day for 10 days)
Trial: 23479993
Drug: OCA7 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA7 with glucosaminylmuramyldipeptide 0.001 g/day
Trial: 17081536
Drug: Crinone 8%
RxNorm normalized name: Crinone 8% Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinone 8% vaginal P gel (90 mg) administered daily
Trial: 17081536
Drug: Utrogestan vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utrogestan vaginal capsules (2 x 100 mg) administered three times daily
Trial: 17081536
Drug: Crinone 8%
RxNorm normalized name: Crinone 8% Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinone 8% vaginal P gel
Trial: 17081536
Drug: Utrogestan vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utrogestan vaginal capsules
Trial: 16128936
Drug: Esomeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) for 7 days (E20-7d)
Trial: 16128936
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg b.i.d.) with the same antibiotics for 7 days (E40-7d)
Trial: 16128936
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg b.i.d.) with the same antibiotics for 10 days (E40-10d)
Trial: 10465924
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg hydromorphone s.c.
Trial: 10465924
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg meperidine i.m.
Trial: 2259918
Drug: NOAC I
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOAC I (high-dose cytarabine 3 g/m2/12 h on day 1 + mitoxantrone 10 mg/m2/d on days 2 and 3)
Trial: 2259918
Drug: NOAC II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOAC II (high-dose cytarabine 3 g/m2/12 h on days 1 and 2 + mitoxantrone 10 mg/m2/d on days 2 and 3) with rhGM‐CSF
Trial: 2259918
Drug: NOAC II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOAC II (high-dose cytarabine 3 g/m2/12 h on days 1 and 2 + mitoxantrone 10 mg/m2/d on days 2 and 3) without rhGM‐CSF
Trial: 385094
Drug: Lithium in
RxNorm normalized name: Product containing lithium in cutaneous dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium in combination with tryptophan (Optimax)
Trial: 31988481
Drug: The Daily
RxNorm normalized name: TITANIUM DIOXIDE 0.036 g in 1 mL / ZINC OXIDE 0.0234 g in 1 mL TOPICAL LOTION [SOOTHE Daily Mineral Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Daily Mile intervention
Trial: 31988481
Drug: The Daily
RxNorm normalized name: TITANIUM DIOXIDE 0.036 g in 1 mL / ZINC OXIDE 0.0234 g in 1 mL TOPICAL LOTION [SOOTHE Daily Mineral Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Daily Mile intervention (specifically in girls)
Trial: 31988481
Drug: The Daily
RxNorm normalized name: TITANIUM DIOXIDE 0.036 g in 1 mL / ZINC OXIDE 0.0234 g in 1 mL TOPICAL LOTION [SOOTHE Daily Mineral Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Daily Mile intervention (economic analysis)
Trial: 28256307
Drug: Budesonide/formoterol pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol pMDI 80/4.5 μg (160/9 μg) BID
Trial: 28256307
Drug: Budesonide/formoterol pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol pMDI 80/2.25 μg (160/4.5 μg) BID
Trial: 28256307
Drug: Budesonide pMDI
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide pMDI 80 μg (160 μg) BID
Trial: 23722456
Drug: 3 consecutive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 consecutive daily intratympanic injections of 4 mg/ml dexamethasone
Trial: 23722456
Drug: 3 consecutive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 consecutive weekly injections of 4 mg/ml dexamethasone
Trial: 15829494
Drug: Temozolomide (TMZ)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (TMZ) 200 mg/m²/day orally for five consecutive days every 4 weeks
Trial: 15829494
Drug: Temozolomide (TMZ)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (TMZ) + Cisplatin (CDDP) 200 mg/m² daily on days 1-5 and 75 mg/m² of CDDP on day 1
Trial: 2586199
Drug: Tamoplex 10
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoplex 10 mg
Trial: 2586199
Drug: Nolvadex 10
RxNorm normalized name: Nolvadex 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nolvadex 10 mg
Trial: 31314107
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy (n = 120)
Trial: 31314107
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (n = 127)
Trial: 28189417
Drug: Nomogram-based FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram-based FSH starting dose (based on multiple biomarkers)
Trial: 28189417
Drug: Age-based FSH
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-based FSH starting dose (150 IU if ≤35 years, 225 IU if >35 years)
Trial: 25384017
Drug: Depression CAREPATH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depression CAREPATH intervention (nurses managing depression at routine home visits with weekly symptom assessment, medication management, care coordination, education, and goal setting)
Trial: 23211762
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (20 mg L and 2 mg Z)
Trial: 23211762
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (10 mg L, 2 mg Z and 10 mg MZ)
Trial: 23211762
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (3 mg L, 2 mg Z and 17 mg MZ)
Trial: 21560845
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose I-131 treatment (150 microCi/gm, initial mean activity 10.2 mCi)
Trial: 21560845
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose I-131 treatment (100 microCi/gm, initial mean activity 8 mCi)
Trial: 21560845
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose I-131 treatment
Trial: 21560845
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose I-131 treatment
Trial: 9476493
Drug: Topical bifonazole
RxNorm normalized name: bifonazole Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bifonazole (Mycospor Solution) alone (group I)
Trial: 9476493
Drug: Topical bifonazole
RxNorm normalized name: bifonazole Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bifonazole (Mycospor Solution) plus 10% urea ointment (Urepearl) (group II)
Trial: 3627208
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of oral corticosteroids (methylprednisolone, 32 mg) approximately 12 hours and 2 hours before challenge with contrast material
Trial: 23701339
Drug: Propofol with
RxNorm normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol with alfentanil (10 μg/kg alfentanil followed by 1 mg/kg propofol, followed by 0.5 mg/kg every 3 minutes as needed)
Trial: 23701339
Drug: Propofol only
RxNorm normalized name: Propofol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol only (1 mg/kg propofol, followed by 0.5 mg/kg every 3 minutes as needed)
Trial: 20963671
Drug: Internet-assisted aftercare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-assisted aftercare group treatment
Trial: 17846859
Drug: HRT (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (oral, transdermal, intranasal)
Trial: 12801957
Drug: Open label
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label infliximab (10 mg/kg)
Trial: 11199363
Drug: White wine
RxNorm normalized name: White wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White wine (300 ml, 8% vol/vol)
Trial: 11199363
Drug: Ethanol solution
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol solution (8% vol/vol)
Trial: 11199363
Drug: Wet swallow
RxNorm normalized name: DRESSING,WET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet swallow (5 ml)
Trial: 11199363
Drug: All beverages
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All beverages (White wine, Ethanol solution, Tap water)
Trial: 3901244
Drug: MOCCA chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOCCA chemotherapy regimen (vincristine, methylprednisolone, and 3 alkylating agents)
Trial: 3901244
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further chemotherapy after 12 months
Trial: 16003672
Drug: Warm-water therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm-water therapy (40 degrees C)
Trial: 16003672
Drug: Cold-water therapy
RxNorm normalized name: Anbesol Cold Sore Therapy
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-water therapy (13 degrees C)
Trial: 8717309
Drug: Steroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid therapy (prednisolone 20‐60 mg/day orally, or pulse therapy)
Trial: 1908630
Drug: Slow-release nifedipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release nifedipine (20 mg at 10 P.M. or 2 doses of 20 mg at 10 P.M. and 6 A.M.)
Trial: 6815153
Drug: Incentive +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentive + problem-solve procedure (combination of incentive and problem-solve techniques)